Abstract

Pyrvinium pamoate (PP), an FDA-approved anthelmintic drug, has been validated as a highly potent anti-cancer agent and patented recently as a potential chemotherapeutic drug for various cancers. The aims of this study were, therefore, to investigate the ability of PP in anti-proliferative activity and focused on the lipid profiles revealing the alteration of specific lipid species in the liver fluke Opisthorchis viverrini (Ov)-associated cholangiocarcinoma (CCA) cells. PP inhibited CCA cell viability through suppressing mitochondrial membrane potential (MMP) and ATP productions, leading to apoptotic cell death. Liquid chromatography-mass spectrometry combined with chemometrics was performed to investigate lipid alteration during PP-induced apoptosis. The lipidomic analyses showed the altered lipid signatures of CCA cell types including S-acetyldihydrolipoamide, methylselenopyruvate, and triglycerides that were increased in PP-treated CCA cells. In contrast, the levels of sphinganine and phosphatidylinositol were lower in the PP-treated group compared with its counterpart. The orthogonal partial-least squares regression analysis revealed that PP-induced MMP dysfunction, leading to remarkably reduced ATP level, was significantly associated with triglyceride (TG) accumulation observed in PP-treated CCA cells. Our findings indicate that PP could suppress the MMP function, which causes inhibition of CCA cell viability through lipid production, resulting in apoptotic induction in CCA cells. These findings provide an anti-cancer mechanism of PP under apoptotic induction ability that may serve as the alternative approach for CCA treatment.

Highlights

  • Cholangiocarcinoma (CCA) is a bile duct cancer that originates from the cholangiocyte lining of biliary tracts

  • We found that Pyrvinium pamoate (PP) decreased CCA cell viability in a dose-dependent manner, whereas PP had no effect on normal human dermal fibroblast (NF) (Figure 1)

  • We found that PP is an effective anti-proliferative agent by inhibiting CCA cell viability and inducing apoptosis

Read more

Summary

Introduction

Cholangiocarcinoma (CCA) is a bile duct cancer that originates from the cholangiocyte lining of biliary tracts. CCA is the second most common primary liver cancer worldwide [1]. This cancer occurs most commonly in mainland Southeast Asian countries, especially in Northeast Thailand which is strongly associated with the liver fluke Opisthorchis viverrini (Ov) infection that has the world’s highest incidence rates with the age-standardized incidence varies between 36.3 and 87.7 per 100,000 population in females and males, respectively [2,3,4]. A poor prognosis and low survival rate are burdens for CCA treatment [5, 6]. CCA has poor response to anti-cancer agents based on characteristics of their multidrug resistant phenotypes, leading to complex mechanisms of chemoresistance [7].

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call